Key Takeaways Intuitive Surgical grew 2025 procedures 18% to 3.1M, with revenues up 21% on recurring sales strength.ISRG expanded its da Vinci base 12% and boosted margins despite tariffs and macro pressures.Abbott posted solid device and CGM growth, but Nutrition headwinds may weigh near term.Intuitive Surgical (ISRG) and Abbott Laboratories (ABT) closed 2025 with solid fourth-quarter performances, though their growth trajectories are expected to diverge going forward.Intuitive Surgical remains primarily f ...

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

Tilray Brands (NASDAQ: TLRY), like many other cannabis stocks, has taken investors on a wild roller-coaster ride the past few years, though for the most part, that ride has been downward. The stock soared by more than 10 times in the months after its 2018 IPO. But then, the optimism faded. Over the past five years, Tilray's share price has collapsed by 97%. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" prov ...

North Chicago, Illinois-based Abbott Laboratories (ABT) discovers, develops, manufactures, and sells healthcare products. Valued at $200.5 billion by market cap, ABT is a global leader in the large and growing in-vitro diagnostic market and its products include pharmaceuticals, nutritional, diagnostics, and vascular products. Companies worth $200 billion or more are generally described as “mega-cap stocks,” and ABT definitely fits that description, with its market cap exceeding this threshold, reflecting ...

证券代码：600196 股票简称：复星医药 编号：临2026-025 上海复星医药（集团）股份有限公司 关于控股子公司许可协议的进展公告 二、本次进展 2026年2月24日，复宏汉霖与KGbio签订《修订及部分终止协议》，（其中包括）双方同意终止《2023 年独家许可协议》，并终止印度尼西亚以外的KGBio获许可区域（即"KGbio终止区域"）独家商业化许 可产品及相关权利的许可。 同日，复宏汉霖与Abbott签订《2024年许可协议之修正案》，就《2024年许可协议》项下（其中主要包 括）约定的许可区域作进一步扩展，并增加相应监管里程碑及销售里程碑付款。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、前期合作情况 2019年9月30日、2023年8月25日，本公司控股子公司复宏汉霖与KGbio先后签订《2019年独家许可协 议》《2023年独家许可协议》及《2019年独家许可协议之修正案》，复宏汉霖就许可产品（即斯鲁利单 抗注射液）授予KGbio于约定区域（即约定的东南亚、中东及北非国家）及约定领域内的独家商业化及 相 ...

Abbott (ABT) ended the recent trading session at $115.29, demonstrating a +2.74% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of 1.04%. Meanwhile, the Dow lost 1.66%, and the Nasdaq, a tech-heavy index, lost 1.13%. Shares of the maker of infant formula, medical devices and drugs witnessed a gain of 4.46% over the previous month, beating the performance of the Medical sector with its gain of 0.7%, and the S&P 500's gain of 1.75%.Analysts and ...

Abbott Laboratories (NYSE:ABT) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 2, the price target on Abbott Laboratories (NYSE:ABT) was reduced from $169 to $142 by Barclays analyst Matt Miksic. The analyst reiterated his Overweight rating on the stock, which offers a revised upside potential of almost 27%. Abbott Laboratories (ABT) Likely to Benefit From Nutrition Segment Recovery Miksic’s revisions were based on deflated forecasts and target multiple for ...

"Boring" may be just what the doctor ordered in this volatile market.Over the past few years, the exciting field of artificial intelligence (AI) has captured much of Wall Street's attention and headlines. And sure enough, some of the leaders in AI have produced incredible returns and might continue doing so. However, investors shouldn't ignore businesses that may not be as exciting, but more than make up for that with other qualities that can slowly increase wealth over time.One such company is Abbott Labor ...

Key TakeawaysAbbott Laboratories (ABT) has launched a landmark $20 billion debt offering across eight tranches, ranging from 3-year notes to 40-year bonds, to capitalize on current credit conditions.The Pentagon released a $151.3 billion reconciliation spending plan to Congress, earmarking massive funds for shipbuilding, missile defense, and sixth-generation fighter jets.S&P Global (SPGI) warned that "broader tariff policy uncertainty" remains a top risk to the global credit outlook and a primary trigger fo ...

For the quarter ended December 2025, Abbott (ABT) reported revenue of $11.46 billion, up 4.4% over the same period last year. EPS came in at $1.50, compared to $1.34 in the year-ago quarter.The reported revenue represents a surprise of -2.76% over the Zacks Consensus Estimate of $11.78 billion. With the consensus EPS estimate being $1.50, the EPS surprise was +0.2%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their nex ...